PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.23%
EBIT growth of 22.23% while Biotechnology median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
22.23%
Operating income growth of 22.23% while Biotechnology median is zero. Walter Schloss might see a modest advantage that can expand.
18.34%
Net income growth of 18.34% while Biotechnology median is zero. Walter Schloss might see potential if moderate gains can keep rising.
32.95%
EPS growth of 32.95% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
32.95%
Diluted EPS growth of 32.95% while Biotechnology median is zero. Walter Schloss might see a slight edge that could improve over time.
21.91%
Share growth above Biotechnology median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
21.91%
Diluted share change of 21.91% while Biotechnology median is zero. Walter Schloss might see a slight difference in equity issuance policy.
No Data
No Data available this quarter, please select a different quarter.
46.02%
OCF growth of 46.02% while Biotechnology is zero. Walter Schloss might see a modest positive difference, which can compound over time.
46.06%
FCF growth of 46.06% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8783.56%
Negative 10Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
85.25%
OCF/share CAGR of 85.25% while Biotechnology median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
76.39%
3Y OCF/share growth of 76.39% while Biotechnology median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
-13944.86%
Negative 10Y net income/share CAGR vs. Biotechnology median of 0.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
85.03%
Net income/share CAGR of 85.03% while Biotechnology median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
64.22%
3Y net income/share CAGR of 64.22% while Biotechnology median is zero. Walter Schloss might see a small advantage that can be scaled further.
5293.49%
Equity/share CAGR of 5293.49% while Biotechnology median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
188.65%
5Y equity/share CAGR of 188.65% while Biotechnology median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
367.41%
3Y equity/share CAGR of 367.41% while Biotechnology median is zero. Walter Schloss sees a modest short-term advantage that could compound if momentum persists.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.58%
Assets shrink while Biotechnology median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-38.36%
Negative BV/share change while Biotechnology median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
No Data
No Data available this quarter, please select a different quarter.
-22.17%
R&D dropping while Biotechnology median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
-22.47%
SG&A decline while Biotechnology grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.